Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alkermes plc.ALKS · Entity 2392 | Director | June 12, 2026 | June 13, 2026 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Chief Medical Officer | February 25, 2021 | March 01, 2021 |
| Wave Life Sciences, Inc.WVE · Entity 4976 | Chief Medical Officer | April 09, 2026 | April 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alkermes plc.
Report date June 12, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 25,680 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Sale · Disposed 2,000 · Balance 25,680 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/11/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/11/2026.
Korsana Biosciences, Inc.
Report date February 25, 2021 · Filed March 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,728 |
Reported balance
After 2021-02-25 transaction · row 1
1 source rowRow 1 · 2021-02-25 · Sale · Disposed 2,637 · Balance 42,728 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $4.00, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $4.00, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
Wave Life Sciences, Inc.
Report date April 09, 2026 · Filed April 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 45,625 |
Reported balance
Holding disclosure · report date 2026-04-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 45,625 F1: Consists of restricted share units (RSUs). Each RSU represent the right to receive one ordinary share upon vesting. The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2035-05-27 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-09 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The option vests as to 25% of the shares on May 27, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until May 27, 2029, subject to the Reporting Person's continued service through the applicable vesting date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2036-02-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-04-09 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted share units (RSUs). Each RSU represent the right to receive one ordinary share upon vesting. The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.
F2: The option vests as to 25% of the shares on May 27, 2026, and vests as to an additional 6.25% of the shares quarterly thereafter until May 27, 2029, subject to the Reporting Person's continued service through the applicable vesting date.
F3: The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030, subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 13, 2026 00:04 UTC | Alkermes plc. ALKS · Entity 2392 | SaleOrdinary Shares | 2,000 | $45.10 | $90,200.00 |
DisclosureSEC source: 0001520262-26-000101 · form4.xml · nonDerivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,680 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/11/2026. Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:08 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000093 · form4.xml · derivative · entry 5 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: This award is fully vested in accordance with its terms. F3 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:08 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,475 | $36.95 | $54,501.25 |
DisclosureSEC source: 0001520262-26-000093 · form4.xml · nonDerivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,680 Read SEC document |
| May 21, 2026 Filed May 23, 2026 00:08 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000093 · form4.xml · nonDerivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:08 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-26-000093 · form4.xml · derivative · entry 4 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,409 Underlying: Ordinary Shares · 5,409 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. F2 · derivative.expiration_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. Read SEC document |
| May 20, 2026 Filed May 23, 2026 00:08 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,538 | $0.00 Strike: $36.98 | $0.00 |
DisclosureSEC source: 0001520262-26-000093 · form4.xml · derivative · entry 3 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,538 Underlying: Ordinary Shares · 11,538 shares Expires 2036-05-20 F2 · derivative.exercise_date: Shares subject to the award vest (and if applicable, become exercisable) in full on the earlier of the one-year anniversary of the date of grant or the date of the issuer's next annual general meeting of shareholders that occurs at least 50 weeks after the date of grant. Read SEC document |
| June 08, 2025 Filed Jun 10, 2025 20:37 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-017212 · form4.xml · derivative · entry 3 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 08, 2025 Filed Jun 10, 2025 20:37 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 793 | $31.71 | $25,146.03 |
DisclosureSEC source: 0001127602-25-017212 · form4.xml · nonDerivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,013 Read SEC document |
| June 08, 2025 Filed Jun 10, 2025 20:37 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-017212 · form4.xml · nonDerivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:34 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016208 · form4.xml · derivative · entry 3 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:34 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,924 | $30.61 | $58,893.64 |
DisclosureSEC source: 0001127602-25-016208 · form4.xml · nonDerivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,505 Read SEC document |
| May 31, 2025 Filed Jun 2, 2025 20:34 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 8,013 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-016208 · form4.xml · nonDerivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 21, 2025 Filed May 23, 2025 22:01 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 6,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-015545 · form4.xml · derivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,142 Underlying: Ordinary Shares · 6,142 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/21/2026. Read SEC document |
| May 21, 2025 Filed May 23, 2025 22:01 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 13,474 | $0.00 Strike: $30.53 | $0.00 |
DisclosureSEC source: 0001127602-25-015545 · form4.xml · derivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,474 Underlying: Ordinary Shares · 13,474 shares Expires 2035-05-21 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/21/2026. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 21:04 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019612 · form4.xml · derivative · entry 3 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 21:04 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,465 | $24.10 | $35,306.50 |
DisclosureSEC source: 0001127602-24-019612 · form4.xml · nonDerivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,416 Read SEC document |
| June 29, 2024 Filed Jul 1, 2024 21:04 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 6,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-019612 · form4.xml · nonDerivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 08, 2024 Filed Jun 11, 2024 00:55 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018321 · form4.xml · derivative · entry 3 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,301 Underlying: Ordinary Shares · 3,301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023. Read SEC document |
| June 08, 2024 Filed Jun 11, 2024 00:55 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 793 | $23.91 | $18,960.63 |
DisclosureSEC source: 0001127602-24-018321 · form4.xml · nonDerivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,777 Read SEC document |
| June 08, 2024 Filed Jun 11, 2024 00:55 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-018321 · form4.xml · nonDerivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 21:05 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 17,492 | $0.00 Strike: $23.40 | $0.00 |
DisclosureSEC source: 0001127602-24-017732 · form4.xml · derivative · entry 8 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,492 Underlying: Ordinary Shares · 17,492 shares Expires 2034-05-31 F9 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 5/31/2025. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 21:05 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 8,013 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017732 · form4.xml · derivative · entry 7 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,013 Underlying: Ordinary Shares · 8,013 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F8 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. F8 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 5/31/2025. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 21:05 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 119 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-017732 · form4.xml · derivative · entry 6 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,104 Underlying: Ordinary Shares · 119 shares Expires not disclosed F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 21:05 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 254 | $30.72 Strike: $30.72 | $7,802.88 |
DisclosureSEC source: 0001127602-24-017732 · form4.xml · derivative · entry 5 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,986 Underlying: Ordinary Shares · 254 shares Expires 2033-06-29 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F6 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 21:05 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 231 | $30.86 Strike: $30.86 | $7,128.66 |
DisclosureSEC source: 0001127602-24-017732 · form4.xml · derivative · entry 4 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,785 Underlying: Ordinary Shares · 231 shares Expires 2032-07-07 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 21:05 UTC | Alkermes plc. ALKS · Entity 2392 | OtherRestricted Stock Unit Award · Derivative | 129 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-017732 · form4.xml · derivative · entry 3 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,602 Underlying: Ordinary Shares · 129 shares Expires not disclosed F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023. F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 21:05 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 355 | $28.40 Strike: $28.40 | $10,082.00 |
DisclosureSEC source: 0001127602-24-017732 · form4.xml · derivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,128 Underlying: Ordinary Shares · 355 shares Expires 2032-06-08 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F3 · derivative.exercise_date: Shares subject to the stock option award vest in three equal annual installments commencing on 6/8/2023. Read SEC document |
| November 17, 2023 Filed Jun 4, 2024 21:05 UTC | Alkermes plc. ALKS · Entity 2392 | OtherNon Qualified Stock Option (Right to Buy) · Derivative | 14 | $28.40 Strike: $28.40 | $397.60 |
DisclosureSEC source: 0001127602-24-017732 · form4.xml · derivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728 Underlying: Ordinary Shares · 14 shares Expires 2032-06-08 F1 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. F2 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:37 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020552 · form4.xml · derivative · entry 3 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:37 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 1,430 | $29.88 | $42,728.40 |
DisclosureSEC source: 0001127602-23-020552 · form4.xml · nonDerivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,269 Read SEC document |
| July 07, 2023 Filed Jul 11, 2023 00:37 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 5,957 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-020552 · form4.xml · nonDerivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:37 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019635 · form4.xml · derivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,985 Underlying: Ordinary Shares · 5,985 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/29/2024. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:37 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 12,732 | $0.00 Strike: $31.33 | $0.00 |
DisclosureSEC source: 0001127602-23-019635 · form4.xml · derivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,732 Underlying: Ordinary Shares · 12,732 shares Expires 2033-06-29 F1 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 3,236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018598 · form4.xml · derivative · entry 6 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,473 Underlying: Ordinary Shares · 3,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three equal annual installments commencing on 6/8/2023. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 373 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018598 · form4.xml · derivative · entry 5 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 373 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: This award is fully vested in accordance with its terms. F2 · derivative.expiration_date: This award is fully vested in accordance with its terms. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:52 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 777 | $31.54 | $24,506.58 |
DisclosureSEC source: 0001127602-23-018598 · form4.xml · nonDerivative · entry 4 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,742 Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 3,236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018598 · form4.xml · nonDerivative · entry 3 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:52 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 90 | $31.54 | $2,838.60 |
DisclosureSEC source: 0001127602-23-018598 · form4.xml · nonDerivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283 Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:52 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 373 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-018598 · form4.xml · nonDerivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:25 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 11,554 | $0.00 Strike: $31.48 | $0.00 |
DisclosureSEC source: 0001127602-22-019135 · form4.xml · derivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,554 Underlying: Ordinary Shares · 11,554 shares Expires 2032-07-07 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 7/7/2023. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 20:25 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 5,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-019135 · form4.xml · derivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,957 Underlying: Ordinary Shares · 5,957 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 7/7/2023. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:34 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 17,773 | $0.00 Strike: $28.97 | $0.00 |
DisclosureSEC source: 0001127602-22-017239 · form4.xml · derivative · entry 4 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,773 Underlying: Ordinary Shares · 17,773 shares Expires 2032-06-08 F5 · derivative.exercise_date: Shares subject to the stock option award vest in three annual installments commencing on 6/8/2023. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:34 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 9,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017239 · form4.xml · derivative · entry 3 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,709 Underlying: Ordinary Shares · 9,709 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 6/8/2023. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in three annual installments commencing on 6/8/2023. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:34 UTC | Alkermes plc. ALKS · Entity 2392 | GrantNon Qualified Stock Option (Right to Buy) · Derivative | 714 | $0.00 Strike: $28.97 | $0.00 |
DisclosureSEC source: 0001127602-22-017239 · form4.xml · derivative · entry 2 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714 Underlying: Ordinary Shares · 714 shares Expires 2032-06-08 F3 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in full on 6/8/2023. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:34 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 373 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017239 · form4.xml · derivative · entry 1 Wright Christopher I · CIK 0001838503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373 Underlying: Ordinary Shares · 373 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in full on 6/8/2023. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in full on 6/8/2023. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:17 UTC | Korsana Biosciences, Inc. CYCN · Entity 7698 | SaleCommon Stock | 2,637 | $3.99 | $10,521.63 |
DisclosureSEC source: 0001140361-21-006641 · form4.xml · nonDerivative · entry 1 Wright Christopher I · CIK 0001838503 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,728 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1, 2019. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.80 to $4.00, inclusive. The reporting person will provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.